Central Asia Lumeichun Biotechnology Statistics
Central Asia Lumeichun Biotechnology (ZYLM) Stock Statistics & Valuation Metrics
Total Valuation
Central Asia Lumeichun Biotechnology has a market cap or net worth of $111.59K. The enterprise value is $485.42B.
- Market Cap
- $111.59K
- Enterprise Value
- $485.42B
Share Statistics
Central Asia Lumeichun Biotechnology has 637,681 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 637,681
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Central Asia Lumeichun Biotechnology’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.12%.
- Return on Equity (ROE)
- 0.00
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 0.12%
- Return on Capital Employed (ROCE)
- 0.00
- Revenue Per Employee
- 150.75K
- Profits Per Employee
- 549
- Employee Count
- 8
- Asset Turnover
- 0.37
- Inventory Turnover
- 16.14
Valuation Ratios
The current PE Ratio of Central Asia Lumeichun Biotechnology is -21.05. Central Asia Lumeichun Biotechnology’s PEG ratio is -0.30.
- PE Ratio
- -21.05
- PS Ratio
- 0.87
- PB Ratio
- 1.25
- Price to FCF
- 0.65
- Price to Operating Cash Flow
- 2.06
- PEG Ratio
- -0.30
Income Statement
In the last 12 months, Central Asia Lumeichun Biotechnology had revenue of 1.21M and earned 4,392 in profits. Earnings per share was 0.00.
- Revenue
- 1.21M
- Gross Profit
- 612.18K
- Operating Income
- 8,005
- Pretax Income
- 9,694
- Net Income
- 4,392
- EBITDA
- 8,005
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was 772.10K and capital expenditures -4, giving a free cash flow of 772.10K billion.
- Operating Cash Flow
- 772.10K
- Free Cash Flow
- 772.10K
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Central Asia Lumeichun Biotechnology pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 154.42%
- Earnings Yield
- -4.75%
Stock Price Statistics
- Beta
- 0.65
- 52-Week Price Change
- -96.52%
- 50-Day Moving Average
- 0.17
- 200-Day Moving Average
- 0.32
- Relative Strength Index (RSI)
- 38.51
- Average Volume (3m)
- 743
Financial Position
Central Asia Lumeichun Biotechnology as a current ratio of 5.61, with Debt / Equity ratio of 1.71%
- Current Ratio
- 5.61
- Quick Ratio
- 5.47
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 1.88
- Interest Coverage Ratio
- 39.83
Taxes
In the past 12 months, Central Asia Lumeichun Biotechnology has paid 5,302 in taxes.
- Income Tax
- 5,302
- Effective Tax Rate
- 0.55
Enterprise Valuation
Central Asia Lumeichun Biotechnology EV to EBITDA ratio is 39.52, with an EV/FCF ratio of 0.63.
- EV to Sales
- 0.84
- EV to EBITDA
- 39.52
- EV to Free Cash Flow
- 0.63
- EV to Operating Cash Flow
- 0.63
Balance Sheet
Central Asia Lumeichun Biotechnology has $25.13K in cash and marketable securities with $10.55K in debt, giving a net cash position of $14.58K billion.
- Cash & Marketable Securities
- $25.13K
- Total Debt
- $10.55K
- Net Cash
- $14.58K
- Net Cash Per Share
- $0.02
- Tangible Book Value Per Share
- $0.00
Margins
Gross margin is 83.73%, with operating margin of 0.57%, and net profit margin of -13.11%.
- Gross Margin
- 83.73%
- Operating Margin
- 0.57%
- Pretax Margin
- -13.07%
- Net Profit Margin
- -13.11%
- EBITDA Margin
- 2.13%
- EBIT Margin
- 0.58%
Analyst Forecast
The average price target for Central Asia Lumeichun Biotechnology is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―

